Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia

Background. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice.Materials and methods. From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program.Results. Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %.Conclusion. The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy.

Authors

Institutions

Publication Details

Journal
Oncohematology
Published
2024-12-10
DOI
https://doi.org/10.17650/1818-8346-2024-19-4-115-123
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia

Н. В. Медведева, A. Kopylova, Maiia Soloveva, Г. А. Дудина et al.
1 links
Oncohematology
Multiple Myeloma Research and Treatments
article

Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia

Н. В. Медведева, A. Kopylova, Maiia Soloveva, Г. А. Дудина, Marina Demchenkova, Е. И. Желнова, E. N. Misyurina, V.N. Abramova, Т. И. Поспелова, А Д Гарифуллин, Tatyana Tsyganok, И В Васильева, Н. В. Скворцова, В. И. Бахтина, Ochsana Ochirova, Sergey Voloshin, Galina Kuchma, Л. П. Менделеева, Anna Semenova, A. Yu. Chuprakova, Т. И. Ольховик, Elena Volodicheva, A. V. Korobkin, V. V. Ryabchikova, Е. Г. Кириллова, Ольга Викторовна Пантелеева, Marina V. Kiseleva, Т. А. Митина, Gayane Tumyan, O. S. Kuznetsova, M. V. Solovev, Maria Zakharova, I. S. Usankin, N. R. Solovkova, Yu. S. Gammershmidt, Yu. V. Dolgushina
article en

Abstract

Background. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice.Materials and methods. From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program.Results. Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %.Conclusion. The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy.

OncohematologyVol. 19(4)
Novosibirsk State Medical University (RU), Sakhalin State University (RU), Moscow Clinical Scientific Center (RU), Leningrad Regional Cancer Center (RU), Regional Clinical Hospital No 4 (RU), Ministry of Health of the Russian Federation (RU), Irkutsk Regional Clinical Hospital (RU), Krasnoyarsk Regional Clinical Hospital (RU), Russian Research Institute of Hematology and Transfusiology (RU), City Clinical Hospital (RU), City Clinical Hospital No. 2 (RU), City Clinical Hospital No 31 (RU), Regional Clinical Research (US), State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU), Municipal Autonomous Healthcare Institution (RU), Tula Regional Clinical Hospital (RU), Orenburg Regional Clinical Hospital №2 (RU), Republican Clinical Hospital named after G.G. Kuvatova (RU)
Reduced inequalities
Openalex Percentile: Top 58%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.